Glaukos Corporation Stock price

Equities

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
94.29 USD +1.73% Intraday chart for Glaukos Corporation +8.02% +18.62%
Sales 2024 * 357M Sales 2025 * 445M Capitalization 4.58B
Net income 2024 * -113M Net income 2025 * -74M EV / Sales 2024 * 13.3 x
Net Debt 2024 * 176M Net Debt 2025 * 146M EV / Sales 2025 * 10.6 x
P/E ratio 2024 *
-39.3 x
P/E ratio 2025 *
-58.8 x
Employees 907
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.02%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.33%
1 week+6.19%
Current month+4.63%
1 month+2.45%
3 months+15.19%
6 months+18.26%
Current year+16.61%
More quotes
1 week
87.31
Extreme 87.31
92.71
1 month
83.90
Extreme 83.9
92.71
Current year
74.75
Extreme 74.745
97.24
1 year
45.38
Extreme 45.38
97.24
3 years
33.33
Extreme 33.33
98.29
5 years
23.31
Extreme 23.31
99.00
10 years
14.25
Extreme 14.25
99.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 00-12-31
Director of Finance/CFO 54 16-06-30
President 48 17-05-04
Members of the board TitleAgeSince
Director/Board Member 65 06-12-31
Director/Board Member 69 14-06-30
Director/Board Member 55 14-06-30
More insiders
Date Price Change Volume
24-03-28 94.29 +1.73% 458 709
24-03-27 92.69 +3.33% 452,668
24-03-26 89.7 +1.10% 459,860
24-03-25 88.72 +0.73% 764,120
24-03-22 88.08 +0.64% 790,512

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. The Company is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
92.69 USD
Average target price
104.2 USD
Spread / Average Target
+12.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Glaukos Corporation - Nyse